These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 29194917)

  • 1. Treatment of clozapine-associated obesity and diabetes with exenatide in adults with schizophrenia: A randomized controlled trial (CODEX).
    Siskind DJ; Russell AW; Gamble C; Winckel K; Mayfield K; Hollingworth S; Hickman I; Siskind V; Kisely S
    Diabetes Obes Metab; 2018 Apr; 20(4):1050-1055. PubMed ID: 29194917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic measures 12 months after a randomised controlled trial of treatment of clozapine associated obesity and diabetes with exenatide (CODEX).
    Siskind D; Russell A; Gamble C; Baker A; Cosgrove P; Burton L; Kisely S
    J Psychiatr Res; 2020 May; 124():9-12. PubMed ID: 32087425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial.
    Ishøy PL; Knop FK; Broberg BV; Bak N; Andersen UB; Jørgensen NR; Holst JJ; Glenthøj BY; Ebdrup BH
    Diabetes Obes Metab; 2017 Feb; 19(2):162-171. PubMed ID: 27717222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: A systematic review and individual participant data meta-analysis.
    Siskind D; Hahn M; Correll CU; Fink-Jensen A; Russell AW; Bak N; Broberg BV; Larsen J; Ishøy PL; Vilsbøll T; Knop FK; Kisely S; Ebdrup BH
    Diabetes Obes Metab; 2019 Feb; 21(2):293-302. PubMed ID: 30187620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of clozapine-associated obesity and diabetes with exenatide (CODEX) in adults with schizophrenia: study protocol for a pilot randomised controlled trial.
    Mayfield K; Siskind D; Winckel K; Hollingworth S; Kisely S; Russell AW
    BJPsych Open; 2015 Jun; 1(1):67-73. PubMed ID: 27703725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucagon-like peptide-1 agonists combating clozapine-associated obesity and diabetes.
    Mayfield K; Siskind D; Winckel K; Russell AW; Kisely S; Smith G; Hollingworth S
    J Psychopharmacol; 2016 Mar; 30(3):227-36. PubMed ID: 26801056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of antipsychotic switching on diabetes in chronic schizophrenia.
    Arnoldy R; Curtis J; Samaras K
    Diabet Med; 2014 Mar; 31(3):e16-9. PubMed ID: 24236701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metformin for Clozapine Associated Obesity: A Systematic Review and Meta-Analysis.
    Siskind DJ; Leung J; Russell AW; Wysoczanski D; Kisely S
    PLoS One; 2016; 11(6):e0156208. PubMed ID: 27304831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phenylpropanolamine appears not to promote weight loss in patients with schizophrenia who have gained weight during clozapine treatment.
    Borovicka MC; Fuller MA; Konicki PE; White JC; Steele VM; Jaskiw GE
    J Clin Psychiatry; 2002 Apr; 63(4):345-8. PubMed ID: 12000209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes.
    Kim D; MacConell L; Zhuang D; Kothare PA; Trautmann M; Fineman M; Taylor K
    Diabetes Care; 2007 Jun; 30(6):1487-93. PubMed ID: 17353504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Weight loss associated with exenatide in an obese man with diabetes commenced on clozapine.
    Siskind D; Wysoczanski D; Russell A; Ashford M
    Aust N Z J Psychiatry; 2016 Jul; 50(7):702-3. PubMed ID: 26979099
    [No Abstract]   [Full Text] [Related]  

  • 12. CoMET: a protocol for a randomised controlled trial of co-commencement of METformin as an adjunctive treatment to attenuate weight gain and metabolic syndrome in patients with schizophrenia newly commenced on clozapine.
    Siskind D; Friend N; Russell A; McGrath JJ; Lim C; Patterson S; Flaws D; Stedman T; Moudgil V; Sardinha S; Suetani S; Kisely S; Winckel K; Baker A
    BMJ Open; 2018 Mar; 8(3):e021000. PubMed ID: 29500217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. One-year follow-up on liraglutide treatment for prediabetes and overweight/obesity in clozapine- or olanzapine-treated patients.
    Svensson CK; Larsen JR; Vedtofte L; Jakobsen MSL; Jespersen HR; Jakobsen MI; Koyuncu K; Schjerning O; Nielsen J; Ekstrøm CT; Correll CU; Vilsbøll T; Fink-Jensen A
    Acta Psychiatr Scand; 2019 Jan; 139(1):26-36. PubMed ID: 30374965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association among weight change, glycemic control, and markers of cardiovascular risk with exenatide once weekly: a pooled analysis of patients with type 2 diabetes.
    Blonde L; Pencek R; MacConell L
    Cardiovasc Diabetol; 2015 Feb; 14():12. PubMed ID: 25645567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity: a 16-week open-label extension phase and both phases of a randomized controlled trial.
    Tchoukhine E; Takala P; Hakko H; Raidma M; Putkonen H; Räsänen P; Terevnikov V; Stenberg JH; Eronen M; Joffe G
    J Clin Psychiatry; 2011 Mar; 72(3):326-30. PubMed ID: 20816037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blood levels of glucose and insulin and insulin resistance in patients with schizophrenia on clozapine monotherapy.
    Wysokiński A
    Diabetes Metab Syndr; 2014; 8(4):236-41. PubMed ID: 25311817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of adjunctive metformin on metabolic traits in nondiabetic clozapine-treated patients with schizophrenia and the effect of metformin discontinuation on body weight: a 24-week, randomized, double-blind, placebo-controlled study.
    Chen CH; Huang MC; Kao CF; Lin SK; Kuo PH; Chiu CC; Lu ML
    J Clin Psychiatry; 2013 May; 74(5):e424-30. PubMed ID: 23759461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
    Tzefos M; Harris K; Brackett A
    Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exenatide in obese or overweight patients without diabetes: A systematic review and meta-analyses of randomized controlled trials.
    Su N; Li Y; Xu T; Li L; Kwong JS; Du H; Ren K; Li Q; Li J; Sun X; Li S; Tian H
    Int J Cardiol; 2016 Sep; 219():293-300. PubMed ID: 27343423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exenatide has a pronounced effect on energy intake but not energy expenditure in non-diabetic subjects with obesity: A randomized, double-blind, placebo-controlled trial.
    Basolo A; Burkholder J; Osgood K; Graham A; Bundrick S; Frankl J; Piaggi P; Thearle MS; Krakoff J
    Metabolism; 2018 Aug; 85():116-125. PubMed ID: 29596853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.